$33.00
0.84% today
Nasdaq, Feb 28, 05:19 pm CET
ISIN
US8688731004
Symbol
SRDX

Surmodics Inc Stock price

$33.28
-4.71 12.40% 1M
-6.25 15.81% 6M
-6.32 15.96% YTD
+0.02 0.06% 1Y
-11.60 25.85% 3Y
-2.14 6.04% 5Y
+9.23 38.38% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-2.62 7.30%
ISIN
US8688731004
Symbol
SRDX
Sector

Key metrics

Market capitalization $475.77m
Enterprise Value $478.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.82
P/S ratio (TTM) P/S ratio 3.79
P/B ratio (TTM) P/B ratio 4.26
Revenue growth (TTM) Revenue growth -9.23%
Revenue (TTM) Revenue $125.45m
EBIT (operating result TTM) EBIT $-1.75m
Free Cash Flow (TTM) Free Cash Flow $-1.93m
Cash position $30.15m
EPS (TTM) EPS $-1.02
P/E forward negative
P/S forward 3.62
EV/Sales forward 3.64
Short interest 4.38%
Show more

Is Surmodics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Surmodics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Surmodics Inc forecast:

3x Hold
100%

Analyst Opinions

3 Analysts have issued a Surmodics Inc forecast:

Hold
100%

Financial data from Surmodics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
125 125
9% 9%
100%
- Direct Costs 35 35
10% 10%
28%
90 90
15% 15%
72%
- Selling and Administrative Expenses 45 45
8% 8%
36%
- Research and Development Expense 39 39
9% 9%
31%
6.70 6.70
69% 69%
5%
- Depreciation and Amortization 8.44 8.44
10% 10%
7%
EBIT (Operating Income) EBIT -1.75 -1.75
114% 114%
-1%
Net Profit -14 -14
361% 361%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Surmodics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Surmodics Inc Stock News

Neutral
Business Wire
25 days ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently...
Neutral
Business Wire
29 days ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug...
Neutral
Business Wire
4 months ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Re...
More Surmodics Inc News

Company Profile

SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Head office United States
CEO Gary Maharaj
Employees 389
Founded 1979
Website www.surmodics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today